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Background: Novel facilities such as an intensive observation unit and an outpatient clinic could result
in improving management of patients presenting with atrial fibrillation (AF).
Methods: This observational study enrolled 3475 patients. Group 1 (1120 patients; years 2004-2005)
was managed with standard approach; group 2 (992 patients; years 2006-2007) was managed with
additional intensive observation; group 3 (1363 patients; years 2008-2009) was managed with additional
intensive observation and outpatient clinic. Primary end point was admission to hospital. Secondary
end points included modalities of rhythm conversion and administration of class IC vs class III
antiarrhythmic drugs in patients with AF lasting less than 48 hours.
Results: Lack of rhythm control, comorbidities, diabetes, and age were independent predictors of
hospitalization. Admissions significantly decreased from group 1 (50%) to 2 (38%) and to 3 (24%) (P b
.001). Interestingly, more than a quarter of patients in group 3 were referred to the outpatient clinic for
short-term follow-up, eventually avoiding admission. Patients with AF lasting less than 48 hours (n =
2189) and without structural heart disease (n = 1685) achieved sinus rhythm in 89% of cases and were
discharged. In these patients, early administration of antiarrhythmic drugs of class IC and III gained
sinus rhythm in 80% and 20%, respectively (P b .001). Spontaneous conversion occurred in 26%;
electrical, 17%; and pharmacological, 57%.
Conclusions: In patients with AF, beyond the standard approach, the novel organization with an
additional intensive observation unit for early pharmacological interventions and an outpatient clinic for
elective treatment and short-term follow-up significantly reduced admission irrespective of independent
predictors of hospitalizations. Patients without structural heart disease treated with antiarrhythmic drugs
achieved sinus rhythm in 89% of cases, mostly with class IC drugs.
© 2012 Published by Elsevier Inc.⁎ Corresponding author.
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2 A. Conti et al.1. Introduction
The prevalence of atrial fibrillation (AF) has substantially
increased during the last 2 decades because of the aging of
the population, the increasing prevalence of chronic heart
disease, and the more frequent diagnoses by monitoring
devices [1]. At the same time, a substantial increase in the
number of hospitalizations for AF has been observed [2,3].
Indeed, a report of the American Heart Association showed
hospitalizations, with AF as the first-listed diagnosis,
increased by 34% from 1996 to 2001 [4] and by 13% in
the past 2 decades in Europe [5]. This trend is related to the
changing practice pattern with AF management [6] rather
than changes over time in the distribution of age, sex, and
comorbidities [3,7]. Because the development of AF is age
related and the age-adjusted incidence of AF is also rising,
the incidence and prevalence of this condition are expected
to increase in the next few decades [2]. As a consequence,
AF is a costly public health problem, with hospitalizations as
the primary cost driver [8] both in North America and in
Europe [9,10]. Therefore, the aim of the present study was to
assess if, beyond the standard approach, the novel organi-
zation with an additional intensive observation unit for early
pharmacological interventions and an outpatient clinic for
elective treatment and follow-up could avoid admissions
irrespective of independent predictors of hospitalizations.2. Methods
This observational study considered for enrolment AF
patients presenting to the emergency department (ED) of a
tertiary care teaching hospital: Careggi University Hospital,
Florence, Italy. Facilities for triage of patients with suspected
dysrhythmia included an observation unit with monitor-
equipped beds and dedicated personnel such as cardiologists
on call and residents. Coded diagnoses are inserted into an
electronic medical chart, allowing easy identification of all
patients with a diagnosis of interest. Data were collected
from January 2004 to January 2010.
2.1. Patient selection
Consecutive patients complaining of palpitations or
general malaise were considered, and those with AF
documented by an electrocardiogram (ECG) were evaluated
in the ED and enrolled in the study. Exclusion criteria were
age less than 18 years; Killip Class 2 or more; New York
Heart Association functional class III or more; clinically
detectable ongoing complications such as acute coronary
syndrome, stroke, and pulmonary or peripheral embolism;
and hemodynamic instability. Three groups of patients were
analyzed: group 1, patients evaluated in the years 2004-2005;
group 2, patients evaluated in the years 2006-2007; and
group 3, patients evaluated in the years 2008-2009. Alongthese years, in the ED of our hospital, the clinical
management of AF changed because an observation unit
for early pharmacological interventions and an outpatients
clinic for structured follow-up were added to the standard
approach. Thus, group 1 was managed with standard
approach; group 2 was managed with an additional intensive
observation; and group 3 was managed with both an
additional intensive observation and an outpatient clinic.
All patients gave informed consent to participate in the study
and publication of data processing.
The study was conducted according to good clinical
practice and the Helsinki principles. The institutional review
board approved the protocol.
2.2. Definition of subtype of AF
Paroxysmal AF was defined by electrocardiographic
evidence of AF followed by subsequent ECG showing
sinus rhythm or clinical documentation by a physician of
paroxysmal AF; persistent AF was defined when lasting
longer than 7 days or when terminated by therapeutic
treatment; permanent AF (or chronic AF) was defined by the
presence of long-lasting (up to year) serial ECGs showing
only AF and no interim evidence of sinus rhythm; solitary or
lone AF was defined by AF in the absence of overt
cardiovascular disease or precipitating illness [5,11].
2.3. Definition of structural heart disease
Known existing coronary artery disease was defined by
angiographic findings of lesions greater than 50% in any
coronary artery or a history of acute coronary syndrome or
revascularization. The definition of acute or stable coronary
syndromes was derived from the European Society of
Cardiology and American Heart Association guidelines
[12-14]. Cardiomyopathy was defined by the presence of a
reported physician diagnosis or echocardiographic confir-
mation of abnormal dilated left or right ventricles; hyper-
trophic cardiomyopathy was defined by the presence of
severe left ventricular hypertrophy.
2.4. Definition of moderate to severe comorbidities
Hemodynamic instability was defined by the presence of
systolic blood pressure less than 100 mm Hg and/or poor
skin signs and/or altered level of consciousness and/or
severe shortness of breath or pulmonary edema (Advanced
Life Support Protocols, Adult Hemodynamic Instability
Definitions, Policy Reference No. 602, San Luis Obispo
County EMS Agency, ALS Treatment Protocols 2007
[Rev. 11/1/10]; http://www.sloemsa.org/files/602.pdf) [15].
Severe vascular disease included carotid and peripheral
artery disease referring to the presence of a grade of
obstruction greater than 70% in any vessel. Peripheral
arterial disease also referred to a history of intermittent
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Fig. 1 The chart of time to treatment in patients presenting with
AF lasting less than 48 hours. Class ADD, Vaughan-Williams class
of antiarrhythmic drugs.
3Management of atrial fibrillationclaudication or reported physician diagnosis documented
by imaging.
Abnormal kidney function was defined as the presence of
serum creatinine of at least 2.3 mg/dL. Abnormal liver
function was defined as chronic hepatic disease (eg,
cirrhosis) or biochemical evidence of significant hepatic
derangement (eg, bilirubin N2× upper limit of normal, in
association with aspartate aminotransferase/alanine amino-
transferase/alkaline phosphatase N3× upper limit normal)
[4,6]. Severe systemic hypertension was defined by a
reported diagnosis of classification of hypertension in the
third class of the World Health Organization. Overall
cardiovascular comorbidities were eventually defined as
the composite of known existing coronary artery disease,
valvular heart disease, and carotid and peripheral artery
disease. Moderate to severe chronic obstructive pulmonary
disease and dysthyroidism were considered in the presence
of documented medical records.
2.5. Management of patients and study protocol
During the time of triage to the ED, a research nurse
detected vital signs and ECG monitoring on admission
(systolic and diastolic blood pressure, heart rate, ECG
monitoring, oxygen saturation, and breaths per minute)
and prospectively recorded variables used for the risk
stratification and information obtained from patients,
relatives, caregivers, or emergency ambulance crews. The
onset of AF was clinically determined on the basis of
reported symptoms. During the visit, the resident checked the
correctness of the findings and integrated them with data
obtained from patients and from previous hospitals’ freely
accessed folders available on the hospital network. Eventu-
ally, the resident confirmed the diagnosis obtained by ECG
monitoring of the emergency ambulance crews who are
designed to provide a clinical workplace with the maximum
mobility. At the time of the first contact with the resident,
all patients underwent evaluation with medical history,
physical examination, initial 12-lead ECG, plasma level of
troponin I, and blood gas analysis. Blood tests, chest
radiographs, and serial ECGs were performed according to
the clinical conditions during the first-line 6-hour period
inside the ED. All the patients with unclear clinical history
and unclear pattern of clinical presentation were subjected to
urgent echocardiography.
Patients with AF onset of less than 48 hours and without
moderate to severe structural heart disease were considered
eligible for rhythm control. They received immediately
intravenous bolus (in a few minutes) of flecainide (2 mg/
kg), propafenone (2 mg/kg), or amiodarone (5 mg/kg)
[5,11,16-19]. The chart of time to treatment is shown in
Fig. 1. Patients with unclear history of known existing
structural heart disease or patients who were considered as
needing further evaluation (echocardiography, chest radiog-
raphy, serial troponin I) before undergoing pharmacological
treatment were submitted to intensive observation. All thepatients who did not recover sinus rhythmwere considered for
a second dose of drugs previously given, eventually followed
by oral administration up to 24 hours of flecainide (2 mg/kg
plus 100 mg twice a day), propafenone (2 mg/kg plus 150 mg
thrice a day), or amiodarone (5 mg/kg plus 200 mg twice a
day). In patients with acute AF, those who did not recover
sinus rhythm after the first-line approach (inside the ED) and
the second-line approach (inside the intensive observation)
were submitted to emergency cardioversion, eventually after
the 24-hour management at least, to not exceed 48 hours and
to prevent systemic embolism. After direct current cardiover-
sion, patients were observed for a period of 3 to 6 hours to
promptly detect adverse events. Patients with AF lasting more
than 48 hours were submitted to oral anticoagulation and
elective direct current cardioversion. Patients who were
discharged to follow-up in the outpatient clinic were managed
with anticoagulation. Inside the observation unit, they started
Table 1 Baseline clinical characteristics of patients with AF enrolled in the study (N = 3475)
Clinical characteristics Total
(N = 3475)
Group 1
(n = 1120)
P
1 vs 2
Group 2
(n = 992)
P
2 vs 3
Group 3
(n = 1363)
P
3 vs 1
P ANOVA
Age (y SD) 70 ± 113 70 ± 13 NS 70 ± 13 NS 71 ± 12 NS .053
Gender (male) 1695 (49%) 519 (46%) NS 491 (50%) NS 685 (50%) NS .131
Hypertension 1739 (50%) 591 (53%) NS 496 (50%) NS 652 (48%) NS .050
Diabetes mellitus 288 (8%) 88 (8%) NS 85 (9%) NS 115 (8%) NS .812
Comorbidities 1512 (44%) 530 (47%) NS 419 (42%) NS 563 (41%) .009 .007
AF ≥48 h 1286 (37%) 506 (45%) b.001 364 (37%) .006 416 (31%) b.001 b.001
Lack of rhythm control 1414 (41%) 508 (45%) NS 427 (43%) b.001 479 (35%) b.001 b.001
Admission rate 1262 (34%) 557 (50%) b.001 379 (38%) b.001 326 (24%) b.001 b.001
NS, not significant.
4 A. Conti et al.both subcutaneous low–molecular weight heparin and oral
warfarin. Moreover, during the observation period, they
received the education that they needed to know in how to
take anticoagulation both with low–molecular weight heparin
and with warfarin until they gained a target value of
international normalized ratio greater than 2.
Because no standard approach is currently being used in
our setting, no randomization was used; and the therapeutic
approach was at the discretion of the physician on
duty. Patients with AF lasting more than 48 hours were
considered not eligible for early rhythm conversion [5,11].
Eventually, they were subjected to elective electrical
conversion (previous transesophageal echocardiography
or after 3weeks of anticoagulation treatment). Residents
and senior doctors ran our observation unit; cardiologists
were on call. Patients were expected to stay in observation
for no more than 24 hours. Patients were sent to the
outpatients clinic for short-term evaluation in the presence
of increased AF symptoms burden and with limitations of
drug therapy. Patients were admitted in the presence of
moderate to severe comorbidities and unstable hemody-
namic conditions. Patients with spontaneous cardioversion
were considered those who gained sinus rhythm without
any pharmacological treatment.
2.6. End point
The primary end point was admission to hospital.
Secondary end points included modalities of rhythm conver-Table 2 Association between clinical variables and primary end poin
Univariate analysis
OR 95% CI
Lack of rhythm control 9.837 8.409-11.592
Diabetes mellitus 2.421 2.102-2.789
Comorbidities 2.156 1.692-2.749
Age 1.034 1.028-1.041
Hypertension 0.987 0.860-1.134
Male gender 0.930 0.810-1.068
OR, odds ratio; CI, confidence interval.sion and administration of class IC vs class III antiarrhythmic
drugs in patients with AF lasting less than 48 hours.
2.7. Statistical analysis
Summary data are expressed as mean ± SD. Statistical
comparisons of demographic and clinical features among the
3 groups were performed using χ2 test followed by the
Bonferroni test for nonparametric variables as required.
Analysis of variance followed by Scheffe test as appropriate
was used for parametric variables. Univariate and multi-
variate logistic regression analyses were used to define
independent predictors of hospitalization. P values are
2-sided. A P value less than .05 was considered statistically
significant. Calculations were performed with use of version
17, SPSS statistical package (SPSS Inc, Chicago, Illinois).3. Results
3.1. Patients enrolled in the study
From January 2004 to January 2010, 3475 AF patients
presenting to the ED (1.1% of total visits per year) were
enrolled and stratified into 3groups: group 1 (years 2004-
2005) included 1120 patients, group 2 (years 2006-2007)
included 992 patients, and group 3 (years 2008-2009)
included 1363 patients.t at univariate and multivariate analysis
Multivariate analysis
P OR 95% CI P
b.001 8.653 7.343-10.197 b.001
b.001 1.864 1.581-2.197 b.001
b.001 1.700 1.277-2.263 b.001
b.001 1.016 1.009-1.023 b.001
NS – – –
NS – – –
1600
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Group 1 Group 2 Group 3
Fig. 2 Patients enrolled in groups 1, 2 and 3 (black bars); patients
admitted (gray bars). *P b .001.
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Baseline clinical characteristics of enrolled patients are
shown in Table 1. In our population, approximately one-half
of patients showed comorbidities and hypertension; one-
third presented AF lasting more than 48 hours; mean age was
70 years. Nonetheless, in the prospective observational
design of the study, no differences existed among clinical
characteristics of the 3groups of patients including mean age,
gender, hypertension, and diabetes. Conversely, comorbid-
ities were greater in the third group as compared to the first
group; AFs lasting more than 48 hours were lower in the
third group as compared to the other groups, as shown in
Table 1. Overall, 1286 (27%) patients had AF lasting more
than 48 hours. Out of the 2189 remaining patients with AF
lasting less than 48 hours and considered for cardioversion
by immediate pharmacological treatment, 504 (14%) patients
had moderate to severe structural heart disease or moderate
to severe comorbidities; they were not submitted to
immediate pharmacological treatment. Thus, 1685 patients
underwent the study protocol for pharmacological treatment.
At univariate and multivariate analysis, lack of rhythm
control, diabetes mellitus, comorbidities, and age were
independent predictors of hospitalization (Table 2). Overall
admissions significantly decreased when the intensive
observation unit and outpatient clinic were available, as
follows: in group 1, admissions accounted for 50%patients; in
group 2, admissions accounted for 36%; and in group 3,
admissions accounted for 24% (P b .001; Fig. 2). Comorbid-Table 3 Comorbidities and structural heart disease in the 3 groups of
years 2006-2007; group 3, years 2007-2010)
Total 3475 Group 1
1120
P
1
Pulmonary disease (n, %) 202 (6%) 61 (5%) N
Thyroid dysfunction (n, %) 181 (5%) 65 (5%) N
Life expectancy ≤6 mo (n, %) 147 (4%) 42 (3%) N
Other chronic disease (n, %) 297 (9%) 144 (13%) b.
Overall structural heart disease (n, %) 921 (27%) 303 (37%) Nities (n = 1512) included structural heart disease (27%),
thyroid dysfunction (5%), respiratory diseases (6%), life
expectancy less than 6 months (4%), and other chronic
diseases (9%, Table 3). Only chronic disease reduced from
group 1 to group 3 (Table 3). PatientswithAF lasting less than
48 hours (n = 2189, 63%) and without structural heart disease
(n = 1685, 77%) eligible for immediate rhythm control by
pharmacological approach achieved sinus rhythm in 89% (n =
1504) of cases. Spontaneous rhythm conversion occurred in
26% of patients; electrical conversion, 17%; and pharmaco-
logical conversion, 57%. Among patients who underwent
pharmacological rhythm conversion, class IC antiarrhythmic
drugs gained sinus rhythm in 80% of treated patients, whereas
class III drugs did it in 20% (P b .001, Fig. 3), without
differences among the 3 groups (Table 4). Major adverse
effects related to pharmacologic conversionwere as follows: 2
patients developed polymorphic ventricular tachycardia after
the infusion of class IC antiarrhythmic drugs and before
recovering sinus rhythm; 8 patients developed bradycardia
and hypotension after recovering the sinus rhythm. Thus, all
these patients were discharged in sinus rhythm. All the
previous reported major adverse effects were monitored by
observation without any additional treatment.
Of note, in our series, adherence to guidelines was
confirmed by the most prevalent use of class IC antiarrhyth-
mic drugs over class III in all groups of patients of the
3 different periods (P b .001, Table 4). Overall, 60% of
enrolled patients gained sinus rhythm, the most with
pharmacological therapy (n = 1127, 33%). Spontaneous
and electrical rhythm conversions increased from group 1
to group 3 (P b .001), whereas pharmacological rhythm
conversions decreased from group 1 to group 3 (P = .0024);
however, pharmacological conversion remained the most
representative approach in all groups (Table 5).
Finally, in the years 2008-2009, 27% (n = 359) of the
patients of group 3 were subjected to the outpatient clinic
within a mean period of 2 weeks after discharge from the ED.
During the subspecialty consultation, a clinical examination
and ECG were performed. Mean age of patients presenting
to outpatient clinic was 70 years; lack of rhythm control
and comorbidities accounted for a substantial portion: 30%
(n = 109) and 36% (n = 129), respectively. Only 8% (n = 30)
of patients had diabetes, and 70% (n = 250) had sinus rhythm
at discharge from the ED.patients enrolled in the study (group 1, years 2004-2005; group 2,
vs 2
Group 2
992
P
2 vs 3
Group 3
1363
P
1 vs 3
P ANOVA
S 61 (6%) NS 80 (6%) NS NS
S 47 (5%) NS 69 (5%) NS NS
S 42 (4%) NS 63 (5%) NS NS
001 65 (7%) NS 88 (6%) b.001 b.001
S 283 (28%) NS 335 (24%) NS NS
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Fig. 3 Flow diagram of management of patients presenting with
AF lasting less than 48 hours without structural heart disease
and eligible for pharmacological conversion. Class IC AAD vs class
III AAD, P b .001. Class ADD, Vaughan-Williams class of
antiarrhythmic drugs.
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Our study demonstrates that patients presenting with AF
lasting less than 48 hours had a lower rate of admission when
the ED was set with novel planned facilities such as an
intensive observation unit and an outpatient clinic. Indeed,
admission accounted for 50% of patients managed without
facilities, 38% of patients managed with an additional
intensive observation unit, and 24% of patients managedTable 4 Rates of conversion to sinus rhythm by different
pharmacological treatment among the 3 groups of the study in
patients with acute AF (n = 855)
Group 1 Group 2 Group 3
Pharmacological
conversion (n)
293 231 331
Class IC AAD (n,%) 212 (72%) 195 (84%) 280 (85%)
P value b.001 b.001 b.001
Class III AAD (n,%) 81 (28%) 36 (16%) 51 (15%)
AAD, antiarrhythmic drug.with both intensive observation unit and outpatient clinic
(P b .001). Admission was reduced irrespective of
independent predictors of hospitalizations such as lack of
rhythm control, diabetes, comorbidities, and age. Patients
presenting with acute AF lasting less than 48 hours and
without structural heart disease achieved sinus rhythm in
89% of cases, the most with class IC antiarrhythmic drugs,
and were discharged. Class IC antiarrhythmic drugs’
superiority over class III agents was confirmed in all the
3 periods of the study. Thus, emergency room physicians
should be encouraged to use Class IC agents and to agree
with the novel approach to acute AF.
More than a quarter of patients have been sent to the
outpatient clinic for elective treatment and short-term follow-
up, eventually avoiding admission.
Consistent with our findings, previous studies have
reported observation units as a useful choice for improving
the utilization of health care resources [20], especially for
successful treatment of chest pain [21], asthma [22], and
syncope [23] and eventually for treatment of AF, to reduce
in-hospital stay [24]. Another study showed cost savings
with the use of oral rate control agents, appropriate
anticoagulation, and electrical cardioversion, with expedited
referral to an outpatient AF clinic [25]. Indeed, also in our
study, we observed a substantial percentage of pharmaco-
logical cardioversion among groups and a greater proportion
of successful electrical cardioversions through the 6-year
observation period, from 5% in group 1, to 11% in group 2,
and to 15% in group 3. Nonetheless, no strategy to pursue
normal sinus rhythm including antiarrhythmic drug therapy,
conversion, and ablation has definitely been shown to reduce
the risk of stroke and hospitalization [4]. In our setting,
physicians were strongly invited to consider pharmacolog-
ical conversion as first-line treatment [11]. Hence, among
patients who recovered sinus rhythm (n = 2060), pharma-
cological approach was the most representative therapeutic
strategy (n = 1127). Interestingly, when we consider patients
with acute AF and without structural heart disease, adherence
to guidelines was confirmed by the strong prevalent
administration of class IC antiarrhythmic drugs over the
administration of class III drugs in all groups (P b .001).
Previous trials demonstrated that class IC and class III
antiarrhythmic drugs succeeded in decreasing admissions
[16,26]. Additional evidence could result from new antiar-
rhythmic drugs with optimal safety profile for rapid
conversion of AF also in patients with structural heart
disease [27]. Patients with spontaneous cardioversion gained
sinus rhythm without any pharmacological treatment. We
compared the percentage of spontaneous cardioversion
among groups along all the periods of the study. We
observed a higher percentage of spontaneous cardioversion
from group 1 to group 3 even if it did not gain statistical
significance. We considered that this fact was due to
increased awareness of the population about AF symptoms
and that the early presentation to the ED was due to the fear
of symptoms and of complications such as stroke.
Table 5 Modalities of rhythm conversion in all patients with AF enrolled in the study and managed in the 3 different periods (N = 3475)
Total N = 3475 Group 1
n = 1120
P
1 vs 2
Group 2
n = 992
P
2 vs 3
Group 3
n = 1363
P
1 vs 3
P ANOVA
Sinus rhythm (n,%) 2060 (60%) 611 (55%) NS 565 (57%) b.001 884 (65%) b.001 b.001
Spontaneous
conversion (n,%)
562 (16%) 144 (13%) NS 145 (15%) b.001 273 (20%) b.001 b.001
Electrical
conversion (n,%)
370 (11%) 60 (5%) b0.001 107 (11%) b.0108 203 (15%) b.001 b.001
Pharmacological
conversion (n,%)
1127 (33%) 407 (36%) NS 312 (32%) NS 408 (30%) .021 .0024
7Management of atrial fibrillationFinally, in the present study, more than a quarter of
patients of group 3, in the last 2-year period of the study,
were evaluated in the outpatient clinic. In these patients,
because of the presence of one-third of patients with both
comorbidities and lack of rhythm control, admission was
considered a real option without the outpatients clinic.
Moreover, two-third of patients managed with oral rate-
control agents were subjected to elective treatment and short-
term follow-up in the outpatients clinic to reduce frequency
and severity of AF symptoms and further admissions.
Results of follow-up could face future analysis. Although
the criteria for submission to the outpatient clinic were not
standardized and at the discretion of the emergency
physician on duty, we consider this option a remarkable
step for further decrease of hospital admission. Costs of
providing outpatient subspecialty care for patients with AF
should be considered in a dedicated trial. Consistent with this
strategy, a recent large in-hospital observational registry of
AF patients in North America showed that hospitalizations
within 2 years after AF diagnosis were associated with
increased AF symptom burden and with known limitations
of contemporary drug therapy. In this analysis concerning a
real-world population, the authors suggested that interven-
tions to reduce hospitalization should reduce symptom
frequency and severity and improve health-related quality
of life rather than just prevent AF recurrences [28].5. Limitations of the study
There are several weaknesses in our study. The results of
our study have been derived from patients presenting to our
tertiary care teaching hospital and need validation in
other centers. Selection of patients was not randomized;
the 3 groups of patients were drawn from 3 different time
periods; and the emergence of the outpatient clinic, which
was one modality designed to reduce admission, came at a
time of pressure toward reducing admissions by the
hospital's administration. Indeed, our general admission
rate from the EDwas about 20% of patients during the 1990s
and rose to about 25% of patients in the first years of 2000s.
However, our tertiary care community hospital accepts
patients referred from other hospitals for complications likeacute coronary syndromes, pulmonary embolism, severe
trauma, life-threatening tachyarrhythmias, and sepsis.
The reduction in admission frequency between the 3 time
periods might not be the result of the outpatient clinic per se,
but rather the result of the overall increased attention paid to
admission avoidance. However, the intensive observation
unit works in implementing the use of early and aggressive
antiarrhythmic therapy. Moreover, the results in our cohort
of patients are not extensible to the symptomatic general
population because of the exclusion of patients with Killip
class greater than or equal to 2; New York Heart Association
functional class greater than or equal to III; complications
like acute coronary syndrome, stroke, or pulmonary or
peripheral embolism; and hemodynamic instability. Another
possible limitation is due to the fact that, in our series,
duration of AF was based on the clinical history; we aware
that patients often do not feel symptoms until heart rate is
rapid or pressure increases. However, our data suggest that
early administration of class IC antiarrhythmic drugs has a
rapid conversion rate and allows discharge from the ED. This
seems to be the main finding of the manuscript and reduces
the emphasis of the outpatient clinic. We did not use
ibutilide. We aware that ibutilide showed good outcomes in
acute AF patients. However, ibutilide is a costly drug in Italy
(more than 10-fold the cost of amiodarone, propafenone, and
flecainide) and has not been admitted to hospital protocol of
antiarrhythmic drugs by our administration. Moreover, the
need of prolonged ECG monitoring for reported ventricular
tachycardia and torsades de pointes could lead to prolonged
observation and costly management. Finally, the optimal use
of outpatients clinic in patients with AF needs to be
confirmed in a properly designed study beyond the
preliminary results of this observational analysis.6. Conclusion
In patients presenting with AF, beyond the standard
approach, the novel organization with an additional intensive
observation unit for early pharmacological interventions and
an outpatient clinic for elective treatment and short-term
follow-up significantly reduced admission irrespective of
independent predictors of hospitalizations such as lack of
8 A. Conti et al.rhythm control, comorbidities, diabetes, and age. Patients
with acute AF without structural heart disease subjected to
antiarrhythmic drugs achieved sinus rhythm in 89% of cases,
mostly with class IC drugs, and were discharged. More than
a quarter of patients were referred to the outpatient clinic for
elective treatment and follow-up, avoiding admission.References
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